Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-411-0 | CAS number: 140-31-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
N-aminoethylpiperazine: Assessment of Toxicokinetic Properties
CAS number |
140-31-8 |
Chemical name |
LABOTEST-BB LTBB000498; Aminoethylpiperazine; AKOS BBS-00004342; AEP;1-(2-aminoethyl)piperazine; 2-(1-piperazinyl)ethylamine; 1-piperazineethanamine; 2-piperazinoethylamine |
Molecular structure |
|
Molecular formula |
C6H15N3 |
Molecular weight |
129.2 |
Water solubility |
Completely miscible (w/v) (estimated by EPI Suite version 4.0 to be 1 x 106mg/L) |
Vapour pressure |
0.066 mm Hg at 25°C (estimated by EPI Suite version 4.0) |
Log Kow |
-1.57 (estimated by EPI Suite version 4.0) |
Log Koa |
9 (estimated by KOAWIN version 1.67) |
pH |
11.4 (1% aqueous solution) [1] |
Absorption
N-aminoethylpiperzaine (AEP) is used in the manufacture of asphalt additives, corrosion inhibitors and epoxy curing agents among other applications.
AEP has low toxicity by the oral route. No toxicokinetic information of AEP is available in the literature; therefore, estimations are based on published absorption data for analogs of AEP and computer predictions. Although no data are available on the fate of AEP in animals, other ethylamines, e.g., diethylenetriamine (DETA) has been reported to quickly absorb from the GI tract with oral bioavailability of 77-83% in rats [3] while a somewhat lower oral absorption has been reported for triethylenetetramine, ranging between 5 and 18% [4]. Oral bioavailability of AEP in humans has been estimated to be 60% (ACD/ADME Suite QSAR program, v5.0).
The dermal penetration rate (Kp) of an aqueous solution of AEP through human skin has been estimated to be fairly low, at 2.68 x 10-5cm/h (EPA DERMWIN QSAR version 2.00).
AEP has a very low vapour pressure and high octanol:air partitioning (Koa= 9). As a result, inhalation is not expected to be a significant route of exposure under normal conditions.
Distribution
Due to its basic nature, non-lipophilicity (log Pow= -1.6) and low plasma protein binding (~19%), a low volume of distribution (1.1 L/kg) is estimated for AEP in humans by ACD/ADME Suite. No information on the distribution of AEP is available; however, its distribution is expected to be similar to related molecules. The absorbed dose of another ethylamine, DETA, has been reported to distribute to almost all rat tissues. However, only about 2% of the administered DETA remained in carcass after 48 hours with over 96% eliminated through excreta and a low (1.3-1.9 ml/kg) volume of distribution calculated for DETA [3], similar to AEP. It is expected that distribution of AEP would be somewhat similar to DETA.
Accumulation
Consistent with low plasma protein binding and low volume of distribution, AEP is expected to rapidly eliminate upon absorption, and bioaccumulation of AEP would be very low. This conclusion is consistent with the fate of other ethylamines, e.g., DETA, which is rapidly eliminated with over 96% of the administered dose recovered within 48 hours in rats [3].
Metabolism
No data on the metabolism of AEP in rat or other species has been reported. As shown in structure, AEP contains the two moieties of ethylenediamine and piperazine. Therefore, it’s metabolism will be predicted based on the metabolism of both ethylenediamine and piperazine.
Some of the earlier metabolism studies on ethylenediamine showed that N-acetylethylene-diamine was a major metabolite in both urine and fecal samples of rats after oral, endotracheal or intravenous administration [3]. This major metabolite was also observed in Swiss Webster mouse study [5]. Other unidentified metabolite (probably assumed as aminoacetaldehyde) and CO2were also detected in these studies [3, 5].
No piperazine metabolism has been reported. However, the metabolism of piperazine derived drughas been studied and reported [6-8]. These studies showed that piperazine metabolite was formed by N-dealkylation and the formed piperazine was further metabolized to ethylenediamine in rat [6-8].
Based on the metabolism data of both ethylenediamine and 1-(3,4-methylenedioxybenzyl)piperazine, the possible metabolites of AEP would be 1-(2-N-acetylaminoethyl)piperazine formed by acetylation of the primary amino group of AEP, piperazine formed by N-dealkylation of the AEP. The formed piperazine can be further metabolized to ethylenediamine by N-dealkylation of the piperazine ring. Other possible aldehyde related metabolites would also be formed as described in ethylenediamine [3,5]. The formed aldehyde metabolites can be finally metabolized to CO2[3,5].
Excretion
The proposed metabolites of AEP would be expected to excrete primarily in urine. The formed aldehyde metabolites can be finally metabolized to CO2and exhaled [3,5].
References
1. Dow online product information – Aminoethylpiperazine (AEP) CAS #000140-31-8, 1-piperazineethaneamine. The Dow Chemical Company,,,http://www.dow.com/amines/prod/ethyl-aep.htm
2. Smyth HF, Carpenter CP, Well CS, Pozzani UC and Striegel, JA (1962). Range-finding toxicity data: list VI. American Indust. Hygiene Assoc. J. 23, 95-107.
3. TR, Lento JW, McKelvey JA and Tallant MJ (1981). Pharmacokinetics and metabolism of diethylenetriamine in the rat. Union Carbide Corporation, Bushy, Export,.
4. Gibbs KR and Walshe JM (1986) The metabolism of trientine: animal studies, in Orphan Diseases and Orphan Drugs (Scheinberg IH and Walshe JM eds) pp 33–42, Manchester University Press in Association with the Fulbright Commission, Manchester, UK. Cited in: Lu J, Chan YK, Camble GD, Popitt SD, Othman AA and Cooper GJS (2007). Triethylenetetramine and Metabolites: Levels in Relation to Copper and Zinc Excretion in Urine of Healthy Volunteers and Type 2 Diabetic Patients. Drug Metab Dispos 35, 221-227.
5. Leung HW (2000) Pharmacokinetics and metabolism of ethylenediamine in the swiss webster mouse following oral or intravenous dosing. Toxicology letters 117, 107-114.
6. Maurer HH, Kraemer T, Springer D and Staack RF (2004) Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Therapeutic drug monitoring 26, 127-131.
7. Staack RF and Maurer HH (2004) New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J Mass Spectrom 39, 255-261.
8. Staack RF, Fritschi G and Maurer HH (2002) Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. Journal of chromatography 773, 35-46.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)